Quadrant Capital Group LLC Mirati Therapeutics, Inc. Transaction History

Quadrant Capital Group LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$41.99 - $62.38 $15,998 - $23,766	381 Added 284.33%	515 $30,000
Q3 2023 Nov 14, 2023	SELL	$27.8 - $45.35 $3,391 - $5,532	-122 Reduced 47.66%	134 $5,000
Q2 2023 Aug 09, 2023	BUY	$36.13 - $49.49 $6,503 - $8,908	180 Added 236.84%	256 $9,000
Q1 2023 May 11, 2023	SELL	$36.54 - $54.26 $14,250 - $21,161	-390 Reduced 83.69%	76 $2,000
Q4 2022 Feb 10, 2023	SELL	$41.27 - $98.62 $22,120 - $52,860	-536 Reduced 53.49%	466 $21,000

Q3 2022 Nov 10, 2022	BUY	$59.5 - $86.7 $17,909 - $26,096	301 Added 42.94%	1,002 $70,000
Q2 2022 Aug 09, 2022	BUY	$39.16 - $88.71 $16,956 - $38,411	433 Added 161.57%	701 $47,000
Q1 2022 May 06, 2022	BUY	$75.82 - $150.97 $19,334 - $38,497	255 Added 1961.54%	268 $22,000
Q4 2021 Feb 01, 2022	SELL	$132.01 - $190.29 $5,148 - $7,421	-39 Reduced 75.0%	13 $2,000
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $5,020 - $6,743	38 Added 271.43%	52 $9,000
Q2 2021 Aug 09, 2021	SELL	$144.0 - $179.73 $288 - $359	-2 Reduced 12.5%	14 $2,000
Q1 2021 May 12, 2021	SELL	$158.92 - $221.61 $3,019 - $4,210	-19 Reduced 54.29%	16 $3,000
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $5,671 - $8,409	35 New	35 $8,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.